Literature DB >> 16867217

p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma.

Sally Hopkins-Donaldson1, Larisa L Belyanskaya, Ana Paula Simões-Wüst, Brigitte Sigrist, Stefanie Kurtz, Uwe Zangemeister-Wittke, Rolf Stahel.   

Abstract

Malignant pleural mesotheliomas (MPMs) are usually wild type for the p53 gene but contain homozygous deletions in the INK4A locus that encodes p14(ARF), an inhibitor of p53-MDM2 interaction. Previous findings suggest that lack of p14(ARF) expression and the presence of SV40 large T antigen (L-Tag) result in p53 inactivation in MPM. We did not detect SV40 L-Tag mRNA in either MPM cell lines or primary cultures, and treatment of p14(ARF)-deficient cells with cisplatin (CDDP) increased both total and phosphorylated p53 and enhanced p53 DNA-binding activity. On incubation with CDDP, levels of positively regulated p53 transcriptional targets p21(WAF), PIG3, MDM2, Bax, and PUMA increased in p14(ARF)-deficient cells, whereas negatively regulated survivin decreased. Significantly, p53-induced apoptosis was activated by CDDP in p14(ARF)-deficient cells, and treatment with p53-specific siRNA rendered them more CDDP-resistant. p53 was also activated by: 1) inhibition of MDM2 (using nutlin-3); 2) transient overexpression of p14(ARF); and 3) targeting of survivin using antisense oligonucleotides. However, it is noteworthy that only survivin downregulation sensitized cells to CDDP-induced apoptosis. These results suggest that p53 is functional in the absence of p14(ARF) in MPM and that targeting of the downstream apoptosis inhibitor survivin can sensitize to CDDP-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16867217      PMCID: PMC1601933          DOI: 10.1593/neo.06148

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  56 in total

1.  Transcriptional repression of the anti-apoptotic survivin gene by wild type p53.

Authors:  William H Hoffman; Siham Biade; Jack T Zilfou; Jiandong Chen; Maureen Murphy
Journal:  J Biol Chem       Date:  2001-11-19       Impact factor: 5.157

2.  Cisplatinum and taxol induce different patterns of p53 phosphorylation.

Authors:  G Damia; L Filiberti; F Vikhanskaya; L Carrassa; Y Taya; M D'incalci; M Broggini
Journal:  Neoplasia       Date:  2001 Jan-Feb       Impact factor: 5.715

3.  Cyclin-dependent kinase inhibitors uncouple cell cycle progression from mitochondrial apoptotic functions in DNA-damaged cancer cells.

Authors:  Hong-Van Le; Andy J Minn; Joan Massagué
Journal:  J Biol Chem       Date:  2005-07-06       Impact factor: 5.157

4.  Inactivation of p53 sensitizes astrocytic glioma cells to BCNU and temozolomide, but not cisplatin.

Authors:  G Wei Xu; Joe S Mymryk; J Gregory Cairncross
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

5.  p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53.

Authors:  C T Yang; L You; K Uematsu; C C Yeh; F McCormick; D M Jablons
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

6.  A mouse model recapitulating molecular features of human mesothelioma.

Authors:  Deborah A Altomare; Charles A Vaslet; Kristine L Skele; Assunta De Rienzo; Karthik Devarajan; Suresh C Jhanwar; Andrea I McClatchey; Agnes B Kane; Joseph R Testa
Journal:  Cancer Res       Date:  2005-09-15       Impact factor: 12.701

7.  Distinct pattern of p53 phosphorylation in human tumors.

Authors:  T Minamoto; T Buschmann; H Habelhah; E Matusevich; H Tahara; A L Boerresen-Dale; C Harris; D Sidransky; Z Ronai
Journal:  Oncogene       Date:  2001-06-07       Impact factor: 9.867

8.  Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.

Authors:  Christian Tovar; James Rosinski; Zoran Filipovic; Brian Higgins; Kenneth Kolinsky; Holly Hilton; Xiaolan Zhao; Binh T Vu; Weiguo Qing; Kathryn Packman; Ola Myklebost; David C Heimbrook; Lyubomir T Vassilev
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-27       Impact factor: 11.205

9.  A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embryonal carcinoma.

Authors:  Joanna S Kerley-Hamilton; Aimee M Pike; Na Li; James DiRenzo; Michael J Spinella
Journal:  Oncogene       Date:  2005-09-08       Impact factor: 9.867

Review 10.  INK4a/ARF: a multifunctional tumor suppressor locus.

Authors:  Norman E Sharpless
Journal:  Mutat Res       Date:  2005-08-25       Impact factor: 2.433

View more
  16 in total

1.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

2.  Expression of p14ARF, MDM2, and MDM4 in human retinoblastoma.

Authors:  Ying Guo; Sanja Pajovic; Brenda L Gallie
Journal:  Biochem Biophys Res Commun       Date:  2008-07-21       Impact factor: 3.575

Review 3.  The role of the mitochondria in mediating cytotoxicity of anti-cancer therapies.

Authors:  Dao M Nguyen; Mustafa Hussain
Journal:  J Bioenerg Biomembr       Date:  2007-02       Impact factor: 3.853

4.  Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis.

Authors:  Deborah A Altomare; Craig W Menges; Jinfei Xu; Jianming Pei; Lili Zhang; Ara Tadevosyan; Erin Neumann-Domer; Zemin Liu; Michele Carbone; Ilse Chudoba; Andres J Klein-Szanto; Joseph R Testa
Journal:  PLoS One       Date:  2011-04-19       Impact factor: 3.240

5.  Sensitivity of global translation to mTOR inhibition in REN cells depends on the equilibrium between eIF4E and 4E-BP1.

Authors:  Stefano Grosso; Elisa Pesce; Daniela Brina; Anne Beugnet; Fabrizio Loreni; Stefano Biffo
Journal:  PLoS One       Date:  2011-12-22       Impact factor: 3.240

6.  Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.

Authors:  Larisa L Belyanskaya; Thomas M Marti; Sally Hopkins-Donaldson; Stefanie Kurtz; Emanuela Felley-Bosco; Rolf A Stahel
Journal:  Mol Cancer       Date:  2007-10-22       Impact factor: 27.401

7.  Expression of cancer-associated molecules in malignant mesothelioma.

Authors:  Ben Davidson
Journal:  Biomark Insights       Date:  2007-05-30

8.  NF2 blocks Snail-mediated p53 suppression in mesothelioma.

Authors:  Jung-Hyun Cho; Su-Jin Lee; Ah-Young Oh; Min-Ho Yoon; Tae-Geun Woo; Bum-Joon Park
Journal:  Oncotarget       Date:  2015-04-30

9.  Zoledronic acid produces combinatory anti-tumor effects with cisplatin on mesothelioma by increasing p53 expression levels.

Authors:  Shinya Okamoto; Yuanyuan Jiang; Kiyoko Kawamura; Masato Shingyoji; Toshihiko Fukamachi; Yuji Tada; Yuichi Takiguchi; Koichiro Tatsumi; Hideaki Shimada; Kenzo Hiroshima; Hiroshi Kobayashi; Masatoshi Tagawa
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

10.  Mechanisms of cisplatin-induced cell death in malignant mesothelioma cells: role of inhibitor of apoptosis proteins (IAPs) and caspases.

Authors:  Inez L Cregan; Arun M Dharmarajan; Simon A Fox
Journal:  Int J Oncol       Date:  2012-11-28       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.